Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jörg, Willuda"'
Autor:
Bertolt Kreft, Karl Ziegelbauer, Rolf Jautelat, Heiner Apeler, Gabriele Leder, Jan Tebbe, Sherif El Sheikh, Rudolf Beier, Frank Dittmer, Jörg Müller, Oliver von Ahsen, Joachim Schuhmacher, Kirk Mclean, Patricia E. Carrigan, Christoph Kneip, Sven Golfier, Claudia Lange, Carol Pena, Beatrix Stelte-Ludwig, Charlotte Kopitz, Hans-Georg Lerchen, Lars Linden, Jörg Willuda
Anti-tumor efficacy of C4.4A-ADC in NSCLC PDX models in mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dc8847329682530dc2e5c6a1fb0a6e9
https://doi.org/10.1158/1535-7163.22503550
https://doi.org/10.1158/1535-7163.22503550
Autor:
Heiner Apeler, Jörg Willuda, Carol Peña, Charlotte Kopitz, Sherif El Sheikh, Claudia Lange, Christoph Kneip, Sven Golfier, Jan Tebbe, Hans-Georg Lerchen, Patricia E. Carrigan, Rolf Jautelat, Gabriele Leder, Joachim Schuhmacher, Rudolf Beier, Kirk Mclean, Beatrix Stelte-Ludwig, Jörg Müller, Karl Ziegelbauer, Frank Dittmer, Oliver von Ahsen, Bertolt Kreft, Lars Linden
Publikováno v:
Molecular cancer therapeutics. 16(5)
C4.4A (LYPD3) has been identified as a cancer- and metastasis-associated internalizing cell surface protein that is expressed in non–small cell lung cancer (NSCLC), with particularly high prevalence in the squamous cell carcinoma (SCC) subtype. Wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51bbe742919c1a15738a98b4f159db21
https://pubmed.ncbi.nlm.nih.gov/28292941
https://pubmed.ncbi.nlm.nih.gov/28292941
Publikováno v:
Antibody Drug Discovery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22813d14541ec54096fc3ec3d853ea6b
https://doi.org/10.1142/9781848166295_0008
https://doi.org/10.1142/9781848166295_0008
Autor:
Kristof Graf, Thore Dietrich, Christiane Schneemann, Kirstin Atrott, Philipp Stawowy, Dietrich Menssen, Jörg Willuda, Eckart Fleck
Publikováno v:
Circulation. 118
A newly developed fusion protein (L19-IL2) consisting of an anti-ED-B fibronectin single chain antibody and the cytokine interleukin-2 (IL2), is a potent antitumor agent for renal cell cancer. ED-B fibronectin (ED-B) is expressed in inflammatory plaq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92976715042e0a3aae307910b16b6bea
https://doi.org/10.1161/circ.118.suppl_18.s_379-b
https://doi.org/10.1161/circ.118.suppl_18.s_379-b
Autor:
Claudio, Di Paolo, Jörg, Willuda, Susanne, Kubetzko, Ikar, Lauffer, Dominique, Tschudi, Robert, Waibel, Andreas, Plückthun, Rolf A, Stahel, Uwe, Zangemeister-Wittke
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(7)
Epithelial cell adhesion molecule (Ep-CAM) is a tumor-associated antigen overexpressed in many solid tumors but shows limited expression in normal epithelial tissues. To exploit this favorable expression pattern for targeted cancer therapy, an Ep-CAM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd8a32bec87ac1dd3da73f618c3ee575
https://pubmed.ncbi.nlm.nih.gov/12855664
https://pubmed.ncbi.nlm.nih.gov/12855664
Autor:
P. August Schubiger, Susanne Kubetzko, Jörg Willuda, Uwe Zangemeister-Wittke, Andreas Plückthun, Robert Waibel
Publikováno v:
ResearcherID
Multimerization of antibody fragments increases the valency and the molecular weight, both identified as key features in the design of the optimal targeting molecule. Here, we report the construction of mono-, di-, and tetrameric variants of the anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d2b8afa9ef259cef5f6fccb04562f6
https://pubmed.ncbi.nlm.nih.gov/11278961
https://pubmed.ncbi.nlm.nih.gov/11278961
Autor:
Anke Krebber, Andreas Plückthun, Susanne Bornhauser, Jörg Willuda, Hans Rudolf Bosshard, Annemarie Honegger, Jörg Burmester
Publikováno v:
Journal of immunological methods. 201(1)
A prerequisite for the use of recombinant antibody technologies starting from hybridomas or immune repertoires is the reliable cloning of functional immunoglobulin genes. For this purpose, a standard phage display system was optimized for robustness,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e728861fea18264b25064e96321416
https://pubmed.ncbi.nlm.nih.gov/9032408
https://pubmed.ncbi.nlm.nih.gov/9032408
Autor:
Pius A. Schubiger, A. Stichelberger, Robert Waibel, A. Egli, Ulrich Abram, Andreas Plückthun, Jean-Pierre Mach, R. Finnern, Jörg Willuda, Roger Alberto, Roger Schibli
Publikováno v:
ResearcherID
We have developed a technetium labeling technology based on a new organometallic chemistry, which involves simple mixing of the novel reagent, a 99m Tc(I)-carbonyl compound, with a His-tagged recombinant protein. This method obviates the labeling of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f359f3a285e06d3e84ffe2999411d9d6
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000082365800033&KeyUID=WOS:000082365800033
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000082365800033&KeyUID=WOS:000082365800033
Autor:
Clive R Wood
Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. The technologies to discover these drugs have been dev
Autor:
Roland E. Kontermann, Stefan Dübel
Antibodies are indispensable tools for research, diagnosis, and therapy. Recombinant approaches allow the modification and improvement of nearly all antibody properties, such as affinity, valency, specificity, stability, serum half-life, effector fun